Open AccessNucleoside inhibitors of reverse transcriptase as a basis for the first line anti-retroviral therapy of HIV infection
Author(s) -
Е. С. Иванова,
Natalia Vorobeva
Publication year - 2017
Publication title -
kliničeskaâ medicina
Language(s) - English
Resource type - Journals
eISSN - 2412-1339
pISSN - 0023-2149
DOI - 10.18821/0023-2149-2017-95-7-656-662
Subject(s) - abacavir , medicine , lamivudine , reverse transcriptase , reverse transcriptase inhibitor , nucleoside reverse transcriptase inhibitor , nucleoside analogue , virology , zidovudine , antiretroviral medication , immunology , human immunodeficiency virus (hiv) , pharmacology , antiretroviral therapy , viral load , virus , nucleoside , viral disease , polymerase chain reaction , gene , hepatitis b virus , biochemistry , chemistry , stereochemistry
Aim. Comparative assessment of safety and effectiveness of various medications used in the first line anti-retroviral therapy (ART) of HIV. Material and methods. Patients with stage IV HIV infection were treated using one of the ART modalities for 48 weeks. 38 patients of group 1 were given fosfazid (Farma K.B, Russia) at a dose of 0.4 twice daily and 41 patients of group 2received abacavir. Both drugs were used in combination with lamivudine and efavirinez at standard doses. The results were evaluated within 0-4-12-24-36 and 48 weeks after ART based on the absence of myelo- and hepatotoxic manifestations, immunological, virological and clinical effectiveness. Results. The safety of ART is evidenced by the absence of myelo- and hepatotoxic symptoms. Fosfazid caused a significant (p<0.05) increase of hemoglobinlevel starting from week 4 up to week 48. No such increase was documented after abacavir therapy. An increaseinthe number of CD4 lymphocyte by 100 cells/mcl suggested positive effect of the treatment on the immune status of all HIV-infected patients. ART inhibited HIV replication in 95% and 88% of the patients in groups 1 and 2 respectively which suggests its high efficiency.